Related Experiment Videos
Pharmacokinetics during pregnancy: evidence-based maternal dose formulation.
1Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas 75235-9032, USA.
Obstetrics and Gynecology
|July 27, 2000
Summary
Drug pharmacokinetics significantly differ in pregnant women, yet current data lacks clinical guidelines for individualized therapy. More research is needed to establish evidence-based treatment protocols during pregnancy.
Area of Science:
- Pharmacology
- Obstetrics
- Drug Metabolism
Background:
- Drug pharmacokinetics (PK) are altered during pregnancy due to physiological changes.
- Understanding these PK differences is crucial for safe and effective drug therapy in pregnant individuals.
Purpose of the Study:
- To systematically review and synthesize existing literature on drug pharmacokinetics in pregnant versus non-pregnant women.
- To identify gaps in knowledge and the need for evidence-based guidelines for drug therapy during pregnancy.
Main Methods:
- Comprehensive literature search of the National Library of Medicine database (1963-1997) using keywords: pregnancy, pharmacokinetics, human.
- Inclusion criteria required primary data from studies comparing pregnant and non-pregnant individuals, reporting key PK parameters.
Main Results:
- 61 articles/book chapters reported relevant pharmacokinetic data from over 1000 initial publications.
- Critically, only two studies provided synthesized data for clinical regimen guidelines.
- Significant variability in pharmacokinetic parameters (e.g., clearance, volume of distribution) was observed.
Conclusions:
- Current pharmacokinetic data during pregnancy is insufficient to formulate evidence-based guidelines for individualized patient therapy.
- There is a critical need for further pharmacokinetic investigations in pregnancy to develop clinical guidelines.
- Recommendations are proposed for minimum reporting standards in obstetric pharmacokinetic studies.